The National Institute for Health and Clinical Excellence (NICE) is no stranger to controversy, but rarely have their decisions ignited such heated debate as their recommendation of drugs to treat dementia. Professor Clive Ballard and Samantha Sharp of the Alzheimer’s Society study the data, marshall their thoughts and articulate concerns about the new recommendations.